NEW DELHI: A government expert panel on
Covid-19 under the Union health ministry has rejected
Eli Lilly’s proposal seeking emergency nod for antibody drug ‘Bamlanivimab’ due to weak efficacy data.
The US-based company had applied for permission to import and market Bamlanivimab (700 mg) in India for the treatment of mild-to-moderate Covid-19, requesting a waiver of clinical trials in the country. The drug belongs to a class called monoclonal antibodies, which were also used in US President
Donald Trump’s Covid-19 treatment in October.